Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

 Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

 Company News
Halozyme Therapeutics, Inc. (HALO) To Present At The UBS 2015 Global Health Care Conference 5/13/2015 10:38:22 AM
Halozyme Therapeutics, Inc. (HALO) Reports First Quarter 2015 Financial Results 5/11/2015 4:57:48 PM
Halozyme Therapeutics, Inc. (HALO) To Present At The Bank of America (BAC) Merrill Lynch 2015 Health Care Conference 5/8/2015 10:38:58 AM
Halozyme Therapeutics, Inc. (HALO) To Host First Quarter 2015 Financial Results Conference Call 5/5/2015 6:39:59 AM
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015 11:11:15 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer 4/13/2015 8:02:30 AM
Halozyme Therapeutics, Inc. (HALO) Provides Update Following Type B FDA Meeting 4/8/2015 1:23:58 PM
Halozyme Therapeutics, Inc. (HALO) Appoints James Mazzola To Lead Corporate Communications, Investor Relations 3/23/2015 7:27:28 AM
Halozyme Therapeutics, Inc. (HALO) Reports Selection Of First Product Candidate Under Janssen Biotech Inc. (JNJ) Collaboration 3/10/2015 7:45:56 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The Barclays 2015 Global Healthcare Conference 3/4/2015 10:24:02 AM